Tuberculosis, Pulmonary
141
17
22
69
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
18 trials with published results (13%)
Research Maturity
69 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.5%
5 terminated out of 141 trials
93.2%
+6.7% vs benchmark
11%
16 trials in Phase 3/4
26%
18 of 69 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 69 completed trials
Clinical Trials (141)
Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Shortened Regimen for Drug-susceptible TB in Children
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
Clinic-based Versus Hotspot-focused Active TB Case Finding
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
Pragmatic Optimized Rifampicin Trial
Bronchoscopic Role in Early Detection of Endobronchial Tuberculosis in Suspected Pulmonary Tuberculosis Patients.
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Digital Health Intervention to Improve TPT Uptake
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
The INSTITUT Study Tuberculosis Nutritional Support
Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets
INSTI's For The Management of HIV-associated TB
Short-course Regimens for the Treatment of Pulmonary Tuberculosis